TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC), a healthcare-focused blank-check company that completed its business combination with TriSalus Life Sciences, Inc. in 2023, filed a 10-Q with the SEC on May 12, 2023. MTAC conducted its initial public offering in 2021 and targeted the medical technology and oncology sectors. TriSalus Life Sciences develops minimally invasive drug-delivery platforms designed to treat liver and pancreatic cancers, including its TriNav Infusion System. The quarterly filing reflects the company's financial position during its post-merger transition period following the SPAC closing. For full filing history, sponsor details, and deal analytics on MTAC and the broader SPAC universe, sign up for complete data access at SpacDesk.